Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a report issued on Wednesday,Benzinga reports. They presently have a $31.00 price target on the stock. Wedbush’s price target suggests a potential upside of 136.80% from the company’s current price.

A number of other equities research analysts have also weighed in on the stock. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Bicara Therapeutics has an average rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Stock Up 0.5 %

Bicara Therapeutics stock traded up $0.07 during mid-day trading on Wednesday, reaching $13.09. 24,674 shares of the company’s stock were exchanged, compared to its average volume of 360,016. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09. The stock’s fifty day simple moving average is $15.52.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, equities research analysts anticipate that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Spire Wealth Management acquired a new stake in Bicara Therapeutics during the 4th quarter worth $31,000. SG Americas Securities LLC acquired a new stake in Bicara Therapeutics during the 4th quarter worth $147,000. Cinctive Capital Management LP acquired a new stake in Bicara Therapeutics during the 3rd quarter worth $229,000. Corebridge Financial Inc. acquired a new stake in Bicara Therapeutics during the 4th quarter worth $167,000. Finally, Barclays PLC acquired a new stake in Bicara Therapeutics during the 3rd quarter worth $255,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.